{"result": {"id": "4e413aa0-9164-4e96-8445-eb7485b04cfc", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>SGLT2I<|>ORGANIZATION<|>SGLT2i is a type of medication that helps lower blood pressure in patients with type 2 diabetes and has cardiovascular benefits\")  \n##  \n(\"entity\"<|>GLP-1RA<|>ORGANIZATION<|>GLP-1RA is a medication used for diabetes management that also aids in blood pressure control and offers cardiovascular and renal protection\")  \n##  \n(\"entity\"<|>ACEI<|>ORGANIZATION<|>ACEI is a class of drugs used for treating hypertension, especially in obese patients, without worsening metabolic conditions\")  \n##  \n(\"entity\"<|>ARB<|>ORGANIZATION<|>ARB is a type of antihypertensive drug recommended for obese patients with hypertension\")  \n##  \n(\"entity\"<|>CCB<|>ORGANIZATION<|>CCB is a medication used in the treatment of hypertension, often combined with other drugs for better control\")  \n##  \n(\"entity\"<|>ACCOMPLISH TRIAL<|>EVENT<|>A clinical trial that compared the effectiveness of ACEI combined with CCB or diuretics in obese patients with hypertension\")  \n##  \n(\"relationship\"<|>SGLT2I<|>GLP-1RA<|>Both SGLT2i and GLP-1RA are medications that help control blood pressure in diabetic patients<|>6\")  \n##  \n(\"relationship\"<|>ACEI<|>CCB<|>ACEI and CCB are often combined for hypertension treatment in obese patients<|>7\")  \n##  \n(\"relationship\"<|>ACEI<|>ARB<|>ACEI and ARB are both recommended as initial treatments for hypertension in obese patients<|>7\")  \n##  \n(\"relationship\"<|>ACCOMPLISH TRIAL<|>ACEI<|>The ACCOMPLISH trial studied the effects of ACEI in combination with other drugs for hypertension treatment<|>8\")  \n##  \n(\"relationship\"<|>ACCOMPLISH TRIAL<|>CCB<|>The ACCOMPLISH trial included a comparison of ACEI combined with CCB for hypertension management<|>8\")  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558740, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 491, "prompt_tokens": 2446, "total_tokens": 2937, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 654}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 用 α受体阻滞剂 。对糖尿病合并难治性高血压的患 者 ,可在 3种降压药联用的基础上 ,加用螺内酯。\n　　新型降糖药 SGLT2i和 GLP-1RA可能有助于改 善糖尿病患者的血压控制 。一项荟萃分析结果显示 , SGLT2i和 GLP-1RA可显著降低 2 型糖尿病患者的 血压 ,使收缩压/舒张压分别降低 4.3/2.3 mmHg和 2.9/0.9 mmHg[607] 。此外 , 多项大型临床研究表明 , SGLT2i可以降低糖尿病发生心血管事件、ESRD 和 心血管疾病死亡的风险[608-610]  ,应用时应关注容量变 化 ;GLP-1RA同样具有一定的心肾保护作用[611]  ,应 用时同样需要关注容量变化。\n8.8   高血压合并肥胖\n\n要点 8H   高血压合并肥胖\n　　　· 高血压合并肥胖者建议将目标血压降至 <  140/90 mmHg( Ⅰ , A) , 可 耐 受 者 降 至 < 130/ 80mmHg( Ⅱa,B) 。\n　　　· 降压药的选择应以不恶化肥胖和代谢指标为 基本原则( Ⅰ ,C) 。\n\n　　肥胖患者最常合并高血压 ,其次是糖尿病 。与非 肥胖个体比较 ,高血压合并肥胖者往往需要更多的药 物控制血压 ,且可能表现为难治性高血压、隐蔽性高血 压和 IDH 的比例也更高[612-614] 。肥胖是儿童和青少年 高血压最重要的危险因素。\n　8.8.1   降压治疗   肥胖人群的降压目标与正常体重 人群并无差异 ,建议将目标血压降至<140/90mmHg, 可耐受者降至<130/80mmHg。\n　　建议将改善生活方式与降压药结合 。通过改善生 活方式减重有助于血压控制[615] 。建议高血压合并肥 胖的患者通过低热量饮食和增加体力活动进行减重。\n　　　降压药的选择应以不恶化肥胖和代谢指标为基本 原则 。 高 血 压 合 并 肥 胖 者 初 始 降 压 治 疗 可 使 用 ACEI、ARB或 CCB。多数肥胖患者需要联合治疗才 可充分控制血压 。联合使用利尿剂和 β 受体阻滞剂 时 ,需在其潜在的代谢不良反应与降压疗效以及适应 证之间进行权衡。收缩期高血压患者通过联合治疗实 现并避免心血管事件(ACCOMPLISH)试验亚组分析 表明 ,肥胖患者接受 ACEI联合 CCB或联合利尿剂治 疗 ,心血管结局风险没有差异[616] 。\n\n\n\n　8.8.2  其他干预措施   对于高血压合并肥胖的患者 ,  虽然不宜初始选择 GLP-1RA和葡萄糖依赖性促胰岛  素 多 肽 ( glucose-dependent insulinotropic polype\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_ea00efc6ca22b16104ddd78a343bddf4e57bb203d5a3a37d8c1565fe4bac7e65_v2"}